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1. Introduction 
Large randomized studies in diabetes have established that early intensive glycemic control 
reduces the risk of diabetic microvascular complications, with less impact on macrovascular 
complications 1, 2. In type 2 diabetic patients, further intensive therapy to target normal 
glycated hemoglobin levels also failed to reduce mortality and major cardiovascular events 
3, 4, while it may be rather harmful 5. However, follow-up data of these trials reveal a long-
term influence of early metabolic control on longer cardiovascular outcomes, even though 
the influence on glycemic control has been immediately disappeared after the trials 6, 7. This 
phenomenon has recently been defined as "metabolic memory". In at-risk patients with type 
2 diabetes, intensive intervention with multiple drug combinations and behavior 
modification had similar sustained beneficial effects with respect to vascular complications 
and on rates of death from any cause and from cardiovascular causes 8. Similarly in patients 
with end-stage renal disease (ESRD), intensive interventions to the general risk factors, such 
as high LDL-cholesterol or C-reactive protein, have not been successful in improving their 
cardiovascular outcomes 9, 10, suggesting that the beneficial effect of risk reduction may be 
overwhelmed by accumulated “metabolic memory” by long-term exposure to oxidative 
stress during the progression of renal failure.  
Potential mechanisms for propagating this "memory" are the non-enzymatic glycation of 
cellular and tissue proteins which are conceptualized as advanced glycation end-products 
(AGEs), the generation of which has been implicated to be deeply associated with increased 
oxidative stress as well as hyperglycemia. AGEs, with their receptor (receptor for AGEs, 
RAGE), potentially mediate molecular and cellular pathway leading to metabolic memory. 
Moreover, interaction of the RAGE with AGEs leads to crucial biomedical pathway 
generating intracellular oxidative stress and inflammatory mediators, which could result in 
further amplification of the pathway involved in AGE generation.  
By utilizing genetically engineered mouse models, emerging evidence suggests that 
AGE/RAGE axis is also found to be profoundly associated with non-diabetic, non-uremic 
pathophysiological conditions including 1) atherogenesis, 2) angiogenic response, 3) vascular 
injury, and 4) inflammatory response (see review in 11), many of which are now implicated in 
metabolic syndrome. Numerous truncated forms of RAGE have also been described, and the 
www.intechopen.com
 
Biomedical Science, Engineering and Technology 
 
92
C-terminally truncated soluble form of RAGE has received much attention. Soluble RAGE 
consists of several forms including endogenous secretory RAGE (esRAGE) which is a spliced 
variant of RAGE 12, and a shedded form derived from cell surface RAGE 13, 14. These 
heterogeneous forms of soluble RAGE, carrying all of the extracellular domains but devoid of 
the transmembrane and intracytoplasmic domains, bind ligands including AGEs, and may 
antagonize RAGE signaling in vitro and in vivo. ELISA systems to measure plasma esRAGE 
and total soluble RAGE have been developed, and decreased plasma esRAGE is found to be 
associated with insulin resistance, obesity and metabolic syndrome 15. Moreover, our recent 
observation highlights the direct role of RAGE in adiposity; RAGE deficiency is associated 
with less weight gain, less abdominal fat mass, less adipocyte size, less atherosclerotic lesion 
formation and higher plasma adiponectin than wild type control 16.  
Insulin resistance is the primary mechanism underlying the development of type 2 diabetes 
and is a central component defining the metabolic syndrome, a constellation of abnormalities 
including obesity, hypertension, glucose intolerance, and dyslipidemia. Insulin resistance or 
metabolic syndrome has been defined to be associated with low-grade inflammation, and 
therefore inflammation could contribute in large part to its development 17, implicating an 
intriguing possibility that this pathophysiological condition is also an additional face of 
metabolic memory driven by RAGE axis. Although insulin resistance has been characterized 
by complex factors including genetic determinants, nutritional factors, and lifestyle, growing 
evidence suggests that mediators synthesized from inflammatory cells are critically involved 
in the regulation of insulin action. In brief, insulin binding to its specific receptor stimulates 
tyrosine phosphorylation of insulin receptor substrate (IRS) proteins, which is a crucial step for 
insulin signaling system. Many inflammatory signals appear to induce serine phosphorylation 
of IRS, which could be involved in disruption of insulin-receptor signaling 17. In this chapter, 
we would like to summarize the recent findings regarding pathophysiological roles of RAGE 
and soluble RAGE in insulin resistance and metabolic syndrome. 
2. AGEs 
2.1 AGE formation by glucose and its derivatives 
AGEs are proteins generated by a series of reactions termed the Maillard Reaction. 
Classically, AGE formation has been described by a nonenzymatic reaction between 
proteins and glucose 18, 19. AGEs derive from the spontaneous reaction of carbohydrates with 
amino group of proteins, which undergo from the formation of reversible products (Schiff 
base adducts) to the generation of more stable products (Amadori products). Subsequently, 
complex reactions occur including intermolecular crosslink formation, and cleavage through 
oxidation, dehydration, condensation, cyclization, and other reactions follows, with 
generation of AGEs through a late reaction characterized by fluorescent and brown 
coloration and molecular crosslinkage. Recently, it was confirmed that AGEs are also 
formed by non-enzymatic reaction of reactive carbonyl compounds such as 3-
deoxyglucosone, methylglyoxal resulting from persisting high blood glucose level, and 
oxidative stress associated with the amino residues of proteins.  
2.2 AGEs formation independent of hyperglycemia 
There is also increasing evidence that AGEs are also formed through lipid-derived 
intermediates, resulting in advanced lipoxidation products 20. AGEs might be formed 
directly by autoxidation of free glucose 21, 22. In this pathway, known as autoxidative 
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glycosylation, such reactive oxygen species as hydrogen peroxide were identified as both 
products and catalysts of autoxidation of sugars. Other than diabetes mellitus patients, high 
plasma and tissue levels of AGEs are observed in patients with ESRD. It has been reported 
that no difference was noted in blood AGEs levels between those with and without diabetes 
mellitus among chronic renal failure patients on hemodialysis, which is believed to enhance 
production and accumulation of AGEs in conditions other than hyperglycemia. Local 
accumulation of AGEs is also observed in patients with Alzheimer disease, rheumatoid 
arthritis, arteriosclerosis, cancer, and other diseases, suggesting the involvement of 
inflammation and oxidative stress in the formation of AGEs.  
2.3 Orally absorbed AGEs 
In addition to the endogenously formed, AGEs are abundant in exogenous sources such as 
foods, especially when prepared under elevated temperatures 23. Vlassara’s group has 
extensively examined the role of the exogenous AGEs in several pathological conditions (see 
review in 24). After ingestion, 10% of orally-administered AGEs are absorbed into the 
circulation 25-27, majorities of which are shown to be accumulated in tissues. Among them are 
tissue-reactive α, β-dicarbonyl-containing intermediate products, such as methylglyoxal, 
which has been linked to cellular oxidant stress and apoptosis 28, and terminal products, 
such as ε N-carboxymethyllysine (CML), which is formed by glycoxidation as well as by 
lipoxidation 29-31. Both methylglyoxal and CML have been identified in vivo and are shown 
to be associated with oxidant stress and tissue damage 31-33.  
3. AGEs and endogenous RAGE ligand in insulin resistance or metabolic 
syndrome 
3.1 AGEs in insulin producing and acting tissues 
Importantly, among the multiple targets of bioactive AGEs are also such diverse tissues as 
the pancreatic islet 34, 35, the adipose tissue (adipocyte) 36 and skeletal muscle cells 37, major 
tissues involved in insulin secretion and its actions. Pharmacological inhibition of 
glycoxidation protects against damage to either tissue 33, 38. AGEs are shown to inhibit 
glucose-stimulated insulin secretion from islet through iNOS-dependent nitric oxide 
production 35. Reduced intake of dietary AGEs has also been shown to decrease the 
incidence of type 1 diabetes in NOD mice 39 as well as the formation of atherosclerotic 
lesions in diabetic apolipoprotein E-deficient mice 40.  
3.2 AGEs and insulin resistance in vivo 
AGEs burden is also shown to be associated with impaired endothelial function 41-44. 
Endothelial dysfunction could be profoundly associated with less insulin delivery to the 
skeletal muscle interstitium, leading to decreased insulin-stimulated glucose uptake by the 
skeletal muscle 45-49, which is implicated in the pathogenesis of insulin resistance. More 
directly, the restriction of the AGE content in standard mouse diets was found to markedly 
improve insulin resistance in obese db/db(++) mice 50. More recent observation shows targeted 
reduction of the advanced glycation pathway improved renal function in obesity 51. This 
interesting observation was further supported by the findings that the development of 
insulin resistance and type 2 diabetes during prolonged high-fat feeding are linked to the 
excess AGEs/advanced lipoxidation end products inherent in fatty diets 52.  
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3.3 AGEs and insulin resistance in vitro 
Several evidences also suggest that AGEs affect the function of insulin-target cells in vitro. 
AGEs interact with CD36 in mouse 3T3 and human subcutaneous adipocytes, which is 
associated with down-regulation of leptin expression in adipocyte through reactive oxygen 
species (ROS) system 53. Miele et al showed in L6 skeletal muscle cells that AGEs affect 
glucose metabolism by impairing insulin-induced insulin receptor substrate (IRS) signaling 
through protein kinase Cα-mediated mechanism 37. The same research group also showed in 
the muscle cells that methylglyoxal, an essential source of intracellular AGEs, hampers a key 
insulin signaling molecule 54. Recent observations by Unoki et al also showed that AGEs 
impair insulin signaling in adipocytes by increasing generation of intracellular ROS 55. Thus, 
AGEs may not only induce the debilitating complications of diabetes, but may also 
contribute to the impairment of insulin signaling in insulin-target tissues which could be 
involved in pathophysiology of insulin resistance, metabolic syndrome and diabetes.  
3.4 Endogenous RAGE ligands, insulin resistance and metabolic syndrome 
RAGE also interacts with other endogenous non-glycated peptide ligands including 
S100/calgranulin 56, amphoterin (also termed as high mobility group box 1 protein, 
HMGB1) 57, 58, amyloid fibrills 59, transthyretin 60, and a leukocyte integrin, Mac-1 61, many of 
which are important inflammatory regulators. Some of these inflammatory ligands for 
RAGE may be involved in pathogenesis of obesity and metabolic syndrome. Early studies 
show expression of S100B protein in pre- and mature- adipocyte and is induced during 
adipogenesis 62, 63. Physiological S100B levels appear to closely reflect adipose tissue mass or 
insulin resistance in humans 64-66. HMGB1 is also found to be expressed in human adipose 
tissue with the expression level associated with the fat mass and obesity-associated gene 67. 
Moreover, growing evidences suggest that infiltration of inflammatory cells, including 
macrophages, play fundamental roles in adiposity and metabolic syndrome 68-70. MAC-1, an 
integrin expressed in macrophage, can act as a RAGE ligand 61, and may be involved in 
adipogenesis through interaction with RAGE.  
4. RAGE and its potential link with insulin resistance and metabolic 
syndrome 
4.1 Structure and function of RAGE 
RAGE is a multiligand cell-surface protein that was isolated from bovine lung in 1992 by the 
group of Schmidt and Stern 71, 72. RAGE belongs to the immunoglobulin superfamily of cell 
surface molecules and has an extracellular region containing one “V”-type immunoglobulin 
domain and two “C”-type immunoglobulin domains 71, 72 (Figure 1). The extracellular 
portion of the receptor is followed by a hydrophobic trans-membrane-spanning and then by 
a highly charged, short cytoplasmic domain which is essential for intracellular RAGE 
signaling. RAGE is initially identified as a receptor for CML-modified proteins 73, a major 
AGE in vivo 74. Three-dimensional structure of the recombinant AGE-binding domain by 
using multidimensional heteronuclear NMR spectroscopy revealed that the domain 
assumes a structure similar to those of other immunoglobulin V-type domains 75, 76. Three 
distinct surfaces of the V domain were identified to mediate AGE-V domain interactions 75. 
The site-directed mutagenesis studies identified the basic amino acids which play a key role 
in the AGE binding activities 76. As mentioned in the previous sentence, RAGE also interacts 
with other endogenous non-glycated peptide ligands, many of which are important 
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inflammatory regulators. The common characteristics of these ligands are the presence of 
multiple β-sheets 61, 77, 78. RAGE is thought to interact with these ligands through their 
shared three-dimensional structure.  
 
 
Fig. 1. Numerous truncated forms of RAGE. There are three major spliced variants of RAGE: 
full length, N-terminally truncated, and C-terminally truncated. The C-terminally truncated 
form of RAGE is secreted from the cell and is named endogenously secreted RAGE 
(esRAGE). esRAGE has a V-domain, which is essential for binding with ligands, and is 
capable of competing with RAGE signaling as a decoy receptor. There are other forms of 
soluble RAGE (sRAGE) that are cleaved from cell-surface RAGE by matrix 
metalloproteinases. The ELISA assay for sRAGE measures all soluble forms including 
esRAGE in human plasma, while the ELISA for esRAGE measures only esRAGE, using 
polyclonal antibody raised against the unique C-terminus of the esRAGE sequence. 
4.2 Inflammatory signaling mediated by RAGE 
Ligand engagement of RAGE leads to prolonged inflammation, resulting in a RAGE-
dependent expression of proinflammatory mediators such as monocyte chemoattractant 
protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) 79, 80. RAGE-mediated 
proinflammatory signals could potentially converge with insulin signaling system (Figure 
2). The engagement of RAGE has been reported to induce activation of the transcription 
factor nuclear factor-κB (NF-κB). Recent reports by Harja et al demonstrate that RAGE 
mediates upregulation of VCAM-1 in response to S100b and oxLDL and JNK MAP kinase 
underlies the RAGE ligand-stimulated molecular events 81. It is not known at present 
whether this is also the case in classical insulin target cells. JNK activity is strikingly 
increased in critical metabolic sites (eg. adipose and liver tissues) 82, and is shown to be 
crucial in IRS-1 phosphorylation and consequently insulin resistance 82, 83. Moreover, the 
main pathological consequence of RAGE ligation is the induction of intracellular reactive 
oxygen species (ROS) via NAD(P)H oxidases and other identified mechanisms such as 
mitochondrial electron transport chain 84, which consequently results in oxidative stress in 
the cells 85. Oxidative stress is emerging as a feature of obesity and an important factor in the 
development of insulin resistance 86, 87. Both the NF-kB and JNK pathways can be activated 
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under the conditions of oxidative stress, and this may be important for the ability of ROS to 
mediate insulin resistance.  RAGE has a short cytosolic portion that contains 43 amino acids 
72. So far, adaptors and/or scaffold proteins that interact with the cytosolic tail of RAGE has 
barely been identified. The RAGE mutant lacking the 43-residue C-terminal tail fails to 
activate NF-κB, and expression of the mutant receptor results in a dominant negative effect 
against RAGE-mediated production of proinflammatory cytokines from macrophages 56, 57.  
 
 
Fig. 2. RAGE and insulin signaling. RAGE is known to activate JNK pathway, which could 
phosphorylate serine-residue of insulin receptor substrate (IRS) and inhibit its activity. 
RAGE mediated generation of reactive oxygen spices (ROS) may alternatively influence 
insulin signaing. 
4.3 RAGE and obesity 
A. RAGE, adiposity and atherosclerosis in mouse model 
Recent reports suggest that RAGE could be involved in progression of obesity. Recent study 
in humans shows RAGE mRNA expression in subcutaneous adipose tissues 88. Although 
this study does not delineate which cells in adipose tissue express RAGE, our current animal 
study shows RAGE expression in adipocyte as wells as endothelial cells in adipose tissues 16. 
We have shown by using apo E/RAGE double knockout mice that progression of 
atherosclerosis is closely associated with RAGE-regulated adiposity in non-diabetic 
conditions 16. As shown in Figure 3, apoE-/-RAGE-/- mice fed either with standard or 
atherogenic diet exhibited significantly decreased atherosclerotic plaque area in aorta as 
compared with apoE-/-RAGE+/+ mice. Importantly, apoE-/-RAGE-/- mice also exhibited 
significantly less body weight, epididymal fat weight and epididymal adipocyte size than 
apoE-/-RAGE+/+ mice at 20-weeks of age (Figure 4). Decreased body weight, epididymal fat 
weight, and adipocyte size are associated with higher plasma adiponectin levels and 
decreased atherosclerosis progression. RAGE is involved in adiposity even in apo E+/+ 
genetic background. At 20-weeks of age, epididymal adipocyte size of RAGE-/- mice was 
significantly smaller than that of RAGE+/+ mice (data not shown).  
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Fig. 3. RAGE deficiency suppresses atherosclerotic progression in apoE deficient mice. 
Representative aortas from apoE-/-RAGE+/+ and apoE-/-RAGE-/- mice (20-weeks old) fed 
with atherogenic diet were shown in left panel. Right panel summarizes the quantitative 
analyses. Plaque area was represented as percentages of the total plaque area. Columns 
represent mean ± standard deviation. Black columns represent apoE-/-RAGE+/+ mice, and 
grey columns, apoE-/-RAGE-/- mice. P values were analyzed by Student’s unpaired t-test. 
Reproduced from ref 16. 
B. Roles of inflammatory cells? 
RAGE is also known to play fundamental role in functions of inflammatory cells 61, 89, 90, 
raising an intriguing possibility that RAGE’s function on adiposity may be mediated 
through its function in inflammatory cells infiltrated in adipose tissues. In our study in 
apoE-/- genetic background fed with atherogenic diet, numbers of Mac-3-positive 
inflammatory cells infiltrated in the epididymal adipose tissues of RAGE+/+apoE-/- mice and 
RAGE-/-apoE-/- did not show significant differences, and crown-like structure were barely 
detected in epididymal adipose tissue in both groups even at 20-week of age. In standard 
diet-fed mice, even though the adiposity was significantly different between RAGE+/+apoE-
/- and RAGE-/-apoE-/- mice, crown-like structure were not detected in epididymal adipose 
tissues in both groups even at 20-week of age. Further in apoE+/+ genetic background at 10 
week of age when significantly different pattern of gene expression was observed between 
WT and RAGE-/- mice, no marked differences in expressions of macrophage markers were 
observed as analyzed by gene microarray. At that age, macrophage infiltration in adipose 
tissues is also reported to be scant 91. Thus, it appears infeasible to RAGE acting primarily at 
inflammatory cells at least in early phase of adiposity, while RAGE expressed in endothelial 
cells or adipocyte might play fundamental roles.  
C. RAGE-regulated genes in adipose tissue: gene chip analysis  
To explore potential mechanisms underlying RAGE-regulation of adiposity, mRNA 
expression profile in epididymal adipose tissue was compared between RAGE+/+ and 
RAGE-/- mice using Affymetrix GeneChip Mouse Genome 430 2.0. We isolated total RNA 
from epididymal adipose tissue at 10-weeks of age, at which phenotypic change in 
adipocyte size was not observed. Using 3 µg of total RNA, 59.8% and 61.4% of 45,037 genes 
were revealed to be present in RAGE+/+ and RAGE-/- adipose tissue, respectively. 
Comparison analysis of the genes (RAGE+/+ adipose tissue as base line) revealed that 10.3% 
of the total genes were decreased, while 11.7% increased in RAGE-/- adipose tissue. As 
compared with RAGE+/+ adipose tissue, 623 genes were downregulated to less than a half, 
and 2,470 genes upregulated more than 2 fold in RAGE-/- adipose tissue.  
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Fig. 4. RAGE deficiency is associated with decreased body weight, epididymal fat weight 
and adipocyte size in apolipoprotein E (apoE)-deficient genetic background. (A) 
Comparisons of body weight between apoE-/-RAGE+/+ and apoE-/-RAGE-/- mice fed with 
standard or atherogenic diet. (B) Comparisons of epididymal fat weight between apoE-/-
RAGE+/+ and apoE-/-RAGE-/- mice fed with standard or atherogenic diet. (C) Comparisons 
of adipocyte size in epididymal adipose tissues. Columns represent mean ± standard 
deviation. P values were analyzed by Student’s t-test. Modified from ref 16. 
D. RAGE-regulated genes in adipose tissue: ontology analysis 
To mine specific group of genes involved in adiposity regulated by RAGE, gene ontology 
analyses were performed. Downregulated genes in RAGE-/- adipose tissue were significantly 
accumulated in the ontology terms of metabolic process including acetyl-CoA biosynthetic 
process, neutral lipid biosynthetic process, pyruvate metabolic process, gluconeogenesis, 
glycogen biosynthetic process, and NADPH regeneration. Interestingly, genes involved in fat 
cell differentiation were also identified to be accumulated as down-regulated in RAGE-/- 
adipose tissue. Ontology terms of glucose transport and neutral amino acid transport were 
also significantly extracted as downregulated in RAGE-/- adipose tissue. Insulin receptor 
signaling pathway was a highly significant ontology term downregulated in RAGE-/- adipose 
tissue. On the contrary, many of the genes upregulated in RAGE-/- adipose tissue were 
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accumulated in ontology terms including cell adhesion, endocytosis, T cell activation, 
prostaglandin biosynthesis, protein binding, protein folding, processing and glycoprotein 
biosynthetic process, many of which are known be associated with cellular mechanisms for 
inflammation and defensive process. Nitrogen compound metabolic process, including amino 
acid metabolic process, was also identified to be a significant ontology term upregulated in 
RAGE-/-. Interestingly, upregulated genes in RAGE-/- tissue were also significantly 
accumulated in ontology term for cell redox homeostasis process. 
E. RAGE-regulated genes in adipose tissue: pathway analysis 
To further identify potential pathways involved in RAGE-regulation of adiposity, KEGG 
pathway analyses were performed (Table 1). In accordance with the ontology analyses, 
insulin signaling pathway, pyruvate metabolism, fatty acid biosynthesis and 
gluconeogenesis were identified to be downregulated pathways in RAGE-/- adipose tissue. 
PPAR signaling and adipocytokine signaling were also identified to be downregulated in 
RAGE-/- adipose tissue. Similar to gene ontology analyses, inflammatory pathways 
including cell adhesion molecules and leukocyte transendothelial migration were the 
significant pathways upregulated in RAGE-/- mice. Pathways including amino acid 
metabolic pathways, nitrogen metabolism, glycan biosynthesis, structure and degradation 
were the pathways significantly upregulated in RAGE-/- adipose tissues.  
 
WT>RAGE-/- (>= 3 fold) count P value 
Insulin signaling pathway 4/137 0.0002  
Fatty acid biosynthesis 1/6 0.0146  
ErbB signaling pathway 2/87 0.0179  
Ethylbenzene degradation 1/10 0.0242  
1- and 2-methylnaphthalene degradation 1/20 0.0478  
Jak-STAT signaling pathway 2/151 0.0500  
WT>RAGE (>= 2 fold)   
Alanine and aspartate metabolism 7/33 <0.0001  
Pyruvate metabolism 7/41 <0.0001  
Insulin signaling pathway 12/137 0.0001  
Adipocytokine signaling pathway 6/71 0.0059  
Fatty acid biosynthesis 2/6 0.0077  
Glycerophospholipid metabolism 5/61 0.0134  
Glycerolipid metabolism 4/41 0.0148  
Glutathione metabolism 4/42 0.0160  
Ethylbenzene degradation 2/10 0.0216  
Valine, leucine and isoleucine biosynthesis 2/10 0.0216  
Type II diabetes mellitus 4/46 0.0218  
Metabolism of xenobiotics by cytochrome P450 5/71 0.0245  
Sulfur metabolism 2/11 0.0260  
PPAR signaling pathway 5/74 0.0287  
Propanoate metabolism 3/30 0.0320  
Glycolysis / Gluconeogenesis 4/53 0.0345  
Circadian rhythm 2/13 0.0358  
Table 1. Pathway analyses of the genes differentially expressed in WT vs. RAGE-/- 
epididymal adipose tissue. 
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WT<RAGE-/- (>= 2 fold)   
Arginine and proline metabolism 6/33 0.0008  
Glycine, serine and threonine metabolism 7/47 0.0010  
Glycerolipid metabolism 5/41 0.0128  
N-Glycan degradation 3/15 0.0136  
Cyanoamino acid metabolism 2/6 0.0163  
One carbon pool by folate 3/16 0.0164  
Glycosphingolipid biosynthesis - ganglioseries 3/16 0.0164  
Polyunsaturated fatty acid biosynthesis 3/17 0.0194  
Ether lipid metabolism 4/32 0.0234  
Cell adhesion molecules (CAMs) 10/147 0.0301  
Prostate cancer 7/88 0.0317  
Nitrogen metabolism 3/21 0.0343  
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 
3/21 0.0343  
Glycan structures - biosynthesis 1 8/114 0.0428  
WT<RAGE-/- (>= 3 fold)   
Arginine and proline metabolism 4/33 0.0053  
Polyunsaturated fatty acid biosynthesis 3/17 0.0054  
Glycerolipid metabolism 4/41 0.0114  
Leukocyte transendothelial migration 7/115 0.0118  
Glutathione metabolism 4/42 0.0124  
Cell adhesion molecules (CAMs) 8/147 0.0137  
O-Glycan biosynthesis 3/27 0.0199  
Thyroid cancer 3/28 0.0219  
Glyoxylate and dicarboxylate metabolism 2/14 0.0358  
Glycan structures - biosynthesis 1 6/114 0.0364  
One carbon pool by folate 2/16 0.0459  
Pantothenate and CoA biosynthesis 2/16 0.0459  
 
Table 1. Pathway analyses of the genes differentially expressed in WT vs. RAGE-/- 
epididymal adipose tissue (continuation). 
F. RAGE-regulated genes in adipose tissue: real time RT-PCR confirmation 
Adipogenesis related genes including, lipin 1, peroxisome proliferator-activated receptor 
(PPAR)-γ, adipose differentiation related protein, were shown to be downregulated in 
RAGE-/- mice. Fatty acid binding protein 5, 1-acylglycerol-3-phosphate O-acyltransferase 2, 
diacylglycerol O-acyltransferase 2, monoacylglycerol O-acyltransferase 1, acetoacetyl-CoA 
synthetase, acetyl-coenzyme A carboxylase α were downregulated in RAGE-/- adipose 
tissue, which could be an essential mechanisms for decreased adiposity in RAGE-/- mice. In 
insulin signaling, phosphatidylinositol 3-kinase (p85α), adaptor protein with pleckstrin 
homology and src (APS), sorbin and SH3 domain containing 1 (CAP), insulin receptor 
substrate (IRS) 1 and 3, thymoma viral proto-oncogene 2 / similar to serine/threonine 
kinase (Akt), Protein phosphatase 1 regulatory (inhibitor) subunit 3C, facilitated glucose  
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Fig. 5. Gene microarray, Ontology and KEGG pathway analyses suggest that insulin 
signaling and adipocyte differentiation are the potential pathways regulated by RAGE. (A) 
Figure summarizes the results of Ontology and KEGG pathway analyses. Genes suppressed 
in RAGE-/- adipose tissue were described in black circles. (B) Changes in mRNA expression 
obtained by gene microarray analyses were confirmed by real-time quantitative RT-PCR 
analyses. All changes in gene expression were statistically significance (p<0.05, Student’s t-
test). IRS-1: insulin receptor substrate 1, PI3K: phosphatidylinositol 3-kinase (p85α), AKT: 
thymoma viral proto-oncogene 2 / similar to serine/threonine kinase, APS: adaptor protein 
with pleckstrin homology and src, CAP: sorbin and SH3 domain containing 1, Glut4: 
facilitated glucose transporter member 4, FABP4: fatty acid binding protein 4, PPAR-γ: 
peroxisome proliferator-activated receptor, Steap4: six-transmembrane epithelial antigen of 
prostate 4, ACC: acetyl-coenzyme A carboxylase α, Gldx: glutaredoxin. 
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transporter member 4 (Glut 4) were identified to be downregulated in RAGE-/- adipose 
tissue. Figure 5A shows genes specifically suppressed in RAGE-/- adipose tissue (closed 
circles) in insulin signaling and adipocyte differentiation pathways. Real-time quantitative 
RT-PCR analyses confirmed the genes in the pathways were indeed down-regulated in 
RAGE-/- adipose tissue (Figure 5B). These results altogether suggest direct role of RAGE in 
adiposity. Although in which cell types RAGE is principally working, insulin signaling and 
adipocyte signaling pathway in adipose tissue appear to play important part in RAGE 
regulation of adiposity. 
4.4 RAGE, endothelial dysfunction and insulin resistance 
Impaired insulin action, when assessed by fasting serum insulin levels or the homeostasis 
model assessment of insulin resistance (HOMA-IR) 92, is associated with atherosclerosis and 
an increased risk of myocardial infarction. Insulin resistance is associated with endothelial 
dysfunction 93 and may serve as a link between insulin resistance and atherosclerosis. Recent 
findings by Harja et al highlighted the involvement of RAGE in endothelial dysfunction 81. 
Endothelium-dependent vasorelaxation was tested in isolated mouse aortic rings from apoE–
/– and apoE–/–RAGE–/– mice, and relaxation response to acetylcholine was significantly 
improved in the RAGE deficient mouse. Similarly, impaired endothelial function in diabetic 
obese mice was also shown to be mediated by AGEs/RAGE system, since blockade of AGE-
RAGE interaction by soluble RAGE significantly improved endothelial function 94. Recent 
clinical observations by Linden et al 44 also implies AGEs/RAGE system is involved in 
impaired endothelial function in patients with chronic kidney diseases. Thus, not only by 
the interaction at the cellular signaling level, but RAGE appears to impair endothelial 
function and potentially blood flow in insulin target tissues, leading to insulin resistance in 
vivo. 
5. C-terminally truncated form of RAGE (soluble RAGE, sRAGE) as potential 
biomarkers for cardiovascular diseases, metabolic syndrome and insulin 
resistance 
5.1 Truncated form of RAGE 
Numerous truncated forms of RAGE have recently been described 12, 95-98 (Figure 1). Two 
major spliced variants of RAGE mRNA, N-terminal and C-terminal truncated forms, have 
been most extensively characterized 12. The N-truncated isoform of RAGE mRNA codes 
for a 303-amino-acid protein lacking the N-terminal signal sequence and the first V-like 
extracellular domain. The N-truncated form is incapable of binding with AGEs, since the 
V-domain is critical for binding of the ligand 71. The N-truncated form of RAGE appears 
to be expressed on the cell surface similar to the full-length RAGE, although its biological 
roles remain to be elucidated 99. It has been suggested that this form of RAGE could be 
involved in angiogenic regulation in a fashion independent of the classical RAGE 
signaling pathway 99.  
5.2 Endogenous secretory RAGE (esRAGE) 
The C-terminal truncated form of RAGE lacks the exon 10 sequences encoding the 
transmembrane and intracytoplasmic domains 12. This spliced variant mRNA of RAGE 
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encodes a protein consisting of 347 amino acids with a 22-amino-acid signal sequence, and is 
released from cells. This C-truncated form is now known to be present in human circulation 
and is named endogenous secretory RAGE (esRAGE) 12. Regulation of alternative splicing of 
the RAGE is recently shown to be regulated through G-rich cis-elements and heterogenous 
nuclear ribonucleoprotein H 100. esRAGE was found to be capable of neutralizing the effects 
of AGEs on endothelial cells in culture 12. Adenoviral overexpression of esRAGE in vivo in 
mice reverses diabetic impairment of vascular dysfunction 101. Thus, the decoy function of 
esRAGE may exhibit a feedback mechanism by which esRAGE prevents the activation of 
RAGE signaling.  
5.3 Soluble RAGE generated by shedding 
It has also been suggested that some sRAGE isoforms that could act as decoy receptors 
may be cleaved proteolytically from the native RAGE expressed on the cell surface 102, 
suggesting heterogeneity of the origin and nature of sRAGE. This proteolytic generation 
of sRAGE was initially described as occurring in mice 103. Recent studies suggest that 
ADAM10 and MMP9 to be involved in RAGE shedding 13, 14. ADAM is known as a 
shedase to shed several inflammatory receptors and can be involved in regulation of 
RAGE/sRAGE balance. A RAGE gene polymorphism is shown to be strongly associated 
with higher sRAGE levels, although the mechanism by which the polymorphism alters 
the sRAGE levels remains to be elucidated 104. Thus, the molecular heterogeneity of the 
diverse types of sRAGE in human plasma could exert significant protective effects against 
RAGE-mediated toxicity. However, the endogenous action of sRAGE may not be confined 
to a decoy function against RAGE-signaling. In HMGB1-induced arthritis model, for 
example, sRAGE is found to interact with Mac-1, and act as an important 
proinflammatory and chemotactic molecule 105. Further analyses are warranted to 
understand more about the endogenous activity of sRAGE.  
5.4 Circulating sRAGE and esRAGE in diseases 
A. Circulating sRAGE and cardiovascular diseases 
Since sRAGE and esRAGE may be involved in feedback regulation of the toxic effects of 
RAGE-mediated signaling, recent clinical studies have focused on the potential 
significance of circulating sRAGE and esRAGE in a variety of pathophysiological 
conditions, including atherosclerotic disorders, diabetes, hypertension, Alzheimer’s 
dieases and chronic kidney diseases (Table 2). First, Falcone et al 106 reported that total 
sRAGE levels are significantly lower in patients with angiographically proven coronary 
artery disease (CAD) than in age-matched healthy controls. The association between 
circulating sRAGE and angiographic observations was shown to be dose-dependent, with 
individuals in the lowest quartile of sRAGE exhibiting the highest risk for CAD. 
Importantly, this cohort consisted of a non-diabetic population, suggesting that the 
potential significance of sRAGE is not confined to diabetes. Falcone et al also showed that 
the association between sRAGE and the risk of CAD was independent of other classical 
risk factors. Their findings are reproduced later by several research groups in larger 
numbers of subjects, and are also extended to other atherosclerotic diseases, such as 
carotid atherosclerosis, cerebral ischemia, and aortic valve stenosis (Table 2). Patients with 
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Alzheimer disease have also lower levels of sRAGE in plasma than patients with vascular 
dementia and controls, suggesting a role for the RAGE axis in this clinical entity as  
well 107.  
 
sRAGE  references 
CAD (non-DM) decreased 106, 153, 154 
 increased 124 
Calcified aortic valve stenosis decreased 155 
Carotid atherosclerosis decreased 156 
Cerebral ischemia decreased 157 158 127 
Alzheimer’s disease decreased 107 159 
Endothelial dysfunction decreased 160 
Diabetes (type 1) increased 122 
Diabetes (type 2) increased 123, 124 
 decreased 120, 121 
Hypertension decreased 117 
NASH decreased 118 119 
Chronic kidney disease increased 109, 123, 129, 161 
162 
Oxidative stress and inflammatory markers positively associated 163, 164 
 inversely associated 121 
esRAGE   
Insulin resistance inversely associated 15 
Metabolic syndrome decreased 15 
Diabetes (type 1) decreased 108, 110 
Diabetes (type 2) decreased 15, 113  
Hypertension decreased 15 
NASH decreased 119 
Carotid atherosclerosis decreased 15, 110-112 
 no association 109 
CAD decreased 113, 153 
Altzheimer’s disease decreased 165 
Chronic kidney disease increased 114, 161 162 
Table 2. Levels of circulating soluble RAGE in cardiovascular and metabolic diseases. 
B. Circulating esRAGE and cardiovascular diseases 
Following development of an ELISA system to specifically measure human esRAGE 108, 
we measured plasma esRAGE level and cross-sectionally examined its association with 
atherosclerosis in 203 type 2 diabetic and 134 non-diabetic age- and gender-matched 
subjects 15. esRAGE levels were inversely correlated with carotid and femoral 
atherosclerosis, as measured as intimal-medial thickness (IMT) by arterial ultrasound. 
Stepwise regression analyses revealed that plasma esRAGE was the third strongest and an 
independent factor associated with carotid IMT, following age and systolic blood 
pressure15. Importantly however, when non-diabetic and diabetic groups were separately 
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analyzed, inverse correlation between plasma esRAGE level and IMT was significant in 
non-diabetic population only, suggesting a potential significance of esRAGE in non-
diabetic condition. No association of plasma esRAGE with IMT in diabetes was also 
reported in other study with 110 Caucasian type 2 diabetic subjects 109. Another Japanese 
research group found an inverse correlation between plasma esRAGE and carotid 
atherosclerosis in type 1 110 and type 2 diabetic subjects 111. Recently, the same research 
group also longitudinally examined the predictive significance of plasma esRAGE and 
sRAGE on progression of carotid atherosclerosis, and found that low circulating esRAGE 
level as well as sRAGE level was an independent risk factor for the progression of carotid 
IMT in type 1 diabetic subjects 112. In Chinese type 2 diabetic patients, plasma esRAGE is 
recently shown to be decreased in angiographically-proved patients with coronary artery 
disease than those without it 113.  
C. Low circulating sRAGE as a predictor of cardiovascular diseases 
We also reported an observational cohort study in patients with end-stage renal disease 
(ESRD) and longitudinally evaluated the effect of plasma esRAGE on cardiovascular 
mortality 114. The cohort in that study included 206 ESRD subjects, who had been treated by 
regular hemodialysis for more than 3 months. Even though the plasma esRAGE levels at 
baseline were higher in ESRD subjects than in those without kidney disease, the subjects in 
the lowest tertile of plasma esRAGE levels exhibited significantly higher cardiovascular 
mortality, but not non-cardiovascular mortality. Importantly, even in the subpopulation of 
non-diabetic subjects alone, low circulating esRAGE level was a predictor of cardiovascular 
mortality, independent of the other classical risk factors. Thus, low circulating esRAGE or 
sRAGE level is a potential predictor for atherosclerosis and cardiovascular diseases even in 
non-diabetic population.  
D. Circulating sRAGE, esRAGE and metabolic syndrome 
Several components of metabolic syndrome have been shown to be associated with 
altered plasma sRAGE or esRAGE levels. We first reported that plasma esRAGE levels are 
already decreased in patients with impaired glucose tolerance as compared with those 
with normal glucose tolerance (Figure 6A). Moreover, patients with metabolic syndrome 
showed significantly lower plasma esRAGE than those without it (Figure 6A). Plasma 
esRAGE levels are inversely correlated with many of the components of metabolic 
syndrome including body mass index (Figure 6B), blood pressures, fasting plasma 
glucose, serum triglyceride, and lower HDL-cholesterol levels 15. The majorities of these 
correlations remained significant even when the non-diabetic or type 2 diabetic 
subpopulation was extracted for analyses. An inverse correaltion between esRAGE (or 
sRAGE) and body mass index was also found for control subjects 115, those with type 1 
diabetes 116, and those with ESRD 114. Patients with hypertension have been found to have 
lower plasma sRAGE or esRAGE levels 15, 117. Importantly, our findings also showed that 
plasma esRAGE was also inversely associated with insulin resistance index, HOMA 
(Figure 6B), suggesting esRAGE and sRAGE as potential biomarkers for metabolic 
syndrome and insulin resistance, which could be associated with altered cardiovascular 
outcomes. Both sRAGE and esRAGE are found to be decreased in patients with liver 
steatosis 118, 119, which is know to be deeply associated with visceral fat accumulation and 
insulin resistance. 
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Fig. 6. Plasma esRAGE levels are decreased in glucose intolerance, metabolic syndrome, 
obesity and insulin resistance (A) Left panel demonstrates the levels of plasma esRAGE in 
subjects with normal glucose tolerance (NGT) (n=118), impaired glucose tolerance (IGT) 
(n=16), and type 2 diabetes (DM) (n=203). Right panel compares the plasma esRAGE levels 
in subjects with (n-53) or without (n=282) metabolic syndrome (Met) as characterized by 
modified NCEP criteria. * p<0.05, ANOVA with multiple comparison (Scheffe’s type). (B) 
Plasma esRAGE levels were inversely associated with body mass index or HOMA insulin 
resistance index. Logarithm-transformed HOMA index was used for the analyses because of 
the skewed distribution. Modified from ref 15. 
E. Circulating sRAGE and esRAGE in diabetes 
The findings regarding plasma levels of the soluble form of RAGE in diabetes are quite 
confusing. We and other groups have found that plasma esRAGE level is significantly lower 
in type 1 and type 2 diabetic patients than in non-diabetic controls 15, 110. Plasma sRAGE 
levels have also been shown to be decreased in diabetic subjects 120, 121, although conflicting 
findings have also been reported for type 1 122 and type 2 diabetes 123, 124. We examined 
plasma sRAGE levels by different ELISA system using esRAGE as a standard protein and 
different sets of antibodies against whole RAGE molecule 125. In our hand, type 2 diabetic 
subjects without overt nephropathy (0.60 ± 0.28 ng/ml) exhibited significantly (p<0.001, 
Student’s t-test) lower plasma sRAGE level than non-diabetic controls (0.77 ± 0.34 ng/ml) 11. 
Of note, when diabetic subjects alone were extracted for analyses, a direct association was 
not observed between plasma soluble RAGE (both sRAGE and esRAGE) levels and the 
status of glycemic control (i.e. glycated hemoglobin A1c) 15, 109, 116, 120, 126. Thus, these complex 
findings in diabetic subjects suggest that levels of plasma soluble forms of RAGE are not 
determined simply by status of glycemic control, and that even plasma esRAGE and sRAGE 
levels may be under the control of distinct mechanisms. Recent study suggests that sRAGE 
levels may be significantly influenced by ethnicity 127, which may partially explain 
controversial findings.  
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F. Circulating sRAGE and esRAGE in CKD 
Another important component that can affect plasma sRAGE is the presence of chronic 
kidney disease. It has been shown that, in peripheral monocytes from subjects with varying 
severities of CKD, RAGE expression is closely associated with worsening of CKD and is 
strongly correlated with plasma levels of pentosidine, a marker for AGEs 128. Circulating 
sRAGE levels have been shown to be increased in patients with decreased renal function, 
particularly those with ESRD 109, 123, 129. Our observations revealed that plasma esRAGE 
levels in type 2 diabetic subjects without CKD are lower than non-diabetic controls, which is 
gradually elevated in accordance with progression of CKD 11. Plasma sRAGE levels in 
diabetic subjects without CKD also exhibited significantly lower than those of non-diabetic 
controls 11. Thus, plasma sRAGE and esRAGE are markedly affected by the presence of 
CKD, which might make the interpretation of the role of soluble RAGE quite complicated 
130. It remains to be determined whether the increase in plasma esRAGE in CKD is caused by 
decreased renal function alone or whether esRAGE levels are upregulated to protect against 
toxic effects of the RAGE ligands. Successful kidney transplantation resulted in significant 
decrease in plasma sRAGE 131, implying that the kidneys play a role in sRAGE removal. 
6. RAGE and Soluble RAGE as a therapeutic target against metabolic 
syndrome, insulin resistance and cardiovascular disease? 
6.1 Soluble RAGE as a therapeutic tool in animal disease models 
Potential usefulness of soluble RAGE for prevention and treatment of inflammatory diseases 
has been demonstrated in many animal models. Blockade of RAGE by administration of 
genetically engineered sRAGE successfully prevented the development of micro- 132, 133 and 
macrovascular complications in diabetes 134-136. We have also shown that adenoviral 
overexpression of esRAGE successfully restored the impaired angiogenic response in 
diabetic mice 101. Sakaguchi et al found that administration of sRAGE markedly suppressed 
neointimal formation following arterial injury in non-diabetic mice 137. Soluble RAGE has 
also been shown to effectively prevent the development of diabetes 138, protect against 
tumor growth and metastasis 58, improve the outcome of colitis 56, restore impaired wound 
healing 139, and suppress Alzheimer disease-like conditions 140. These effects of soluble 
RAGE in animal models could be explained by its decoy function, inhibiting RAGE 
interaction with its proinflammatory ligands, which might be applicable to human diseases 
as well. Since our findings strongly suggest the role of RAGE in adiposity, metabolic 
syndrome and atheroslcerosis 16, RAGE/soluble RAGE axis could also be a potential 
therapeutic target against these pathophysiological conditions. 
6.2 Potential regulatory mechanisms of circulating soluble RAGE 
So far, limited findings are available regarding the mechanisms of regulation of circulating 
esRAGE or sRAGE in humans. A tissue microarray technique using a wide variety of adult 
normal human preparations obtained from surgical and autopsy specimens revealed that 
esRAGE was widely distributed in tissues, including vascular endothelium, 
monocyte/macrophage, pneumocytes, and several endocrine organs 141. However, it is 
unclear at present from which organ or tissue plasma sRAGE or esRAGE originate. 
Circulating AGEs may be involved in regulation of the secretion or production of soluble 
RAGE, since AGEs are known to upregulate RAGE expression in vitro 142. esRAGE could be 
simultaneously upregulated by AGEs and act as a negative feedback loop to compensate for 
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the damaging effects of AGEs. We and others have found positive correlations between 
plasma sRAGE or esRAGE and AGEs 11, 114-116, 123. Significant positive correlation between 
plasma esRAGE and pentosidine was observed both in hemodialysis and non-hemodialysis 
subjects 11. However, plasma CML did not significantly correlated with plasma esRAGE 
both in hemodialysis and non-hemodialysis subjects. AGEs-mediated regulation of soluble 
RAGE is also supported by the findings that the suppression of sRAGE expression in 
diabetic rat kidney is reversed by blockade of AGEs accumulation with alagebrium 143. 
Other inflammatory mediators, such as S100, tumor necrosis factor α, and C-reactive 
protein, could also be potential candidates for regulation of the plasma level of soluble 
RAGE in humans 120, 142, 144. Moreover, Geroldi et al 145 showed that high serum sRAGE is 
associated with extreme longevity, suggesting that understanding the intrinsic regulation of 
RAGE and soluble RAGE is important for longevity/anti-aging strategies. Without doubt, 
further understanding of the regulation of soluble RAGE will be most helpful in delineating 
potential targets for therapeutic application of soluble RAGE.  
6.3 Pharmacological agents regulate circulating sRAGE and esRAGE 
A. Angiotensin-converting enzyme inhibitor 
It would be essential to determine whether currently available pharmacological agents can 
regulate plasma sRAGE or esRAGE. Potential agents that may affect circulating soluble 
RAGE include the angiotensin-converting enzyme (ACE) inhibitor 146, thiazolidinediones 
(TZD) 147 and statins 148-150, which are known to modulate the AGEs-RAGE system in 
culture. Forbes et al 146 showed that inhibition of angiotensin-converting enzyme (ACE) in 
rats increased renal expression of sRAGE, and that this was associated with decreases in 
expression of renal full-length RAGE protein. They also showed that plasma sRAGE levels 
were significantly increased by inhibition of ACE in both diabetic rats and in human 
subjects with type 1 diabetes. Thus, one attractive scenario is that the protective effect of 
ACE inhibition against progression of renal dysfunction is mediated through regulation of 
RAGE versus soluble RAGE production.  
B. Statin 
Tam et al recently reported changes in serum levels of sRAGE and esRAGE in archived 
serum samples from a previous randomized double-blind placebo-controlled clinical trial 
that explored the cardiovascular effects of atorvastatin in hypercholesterolemic Chinese type 
2 diabetic patients, and found that atorvastatin can increase circulating esRAGE levels 150.  
C. Thiazolidinedione 
For thiazolidinedione, a randomised, open-label, parallel group study was performed with 
64 participants randomised to receive add-on therapy with either rosiglitazone or 
sulfonylurea to examine the effect on plasma soluble RAGE 151. At 6 months, both 
rosiglitazone and sulfonylurea resulted in a significant reduction in HbA1c, fasting glucose 
and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the 
rosiglitazone group. In a recent study in type 2 diabetes mellitus patients, pioglitazone, but 
not rosiglitazone, significantly raised sRAGE levels 152, suggesting that all thiazolidinedione 
may not act similarly. Nevertheless, thiazolidinedione could be one promising candidate 
which increase circulating levels of esRAGE and sRAGE, and RAGE/soluble RAGE 
regulation may be involved in thiazolidinedione-mediated improvement of insulin 
resistance. Finally, we have started the randomized clinical trial comparing the effect of 
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pioglitazone with glimepiride on plasma sRAGE and esRAGE, expression of RAGE on 
peripheral mononuclear cells, and RAGE shedase gene expression in type 2 diabetic patients 
(UMIN000002055). This study will be of particular importance to understand the regulatory 
mechanisms of sRAGE and esRAGE in clinical setting. 
7. Summary 
The findings discussed here implicated pivotal role of RAGE system in initiation and 
progression of metabolic syndrome, insulin resistance and atherosclerosis. Provided that 
continuous RAGE activation represents the concept of “metabolic memory”, metabolic 
syndrome might be conceptualized as memorized long-term subtle inflammation and 
oxidative stress using RAGE as an inflammatory scaffold. In this system, endogenous 
inflammatory RAGE ligands may be profoundly involved (Figure 7). Further, sRAGE or 
esRAGE could serve as a biomarker as well as a therapeutic target for these disease 
conditions. Obviously there are many missing parts to be veiled to further understand the 
role of RAGE/soluble RAGE axis in metabolic syndrome and insulin resistance. However, 
we believe our findings and this concept would open up a new research field which could 
further precede our understanding of the RAGE biology. 
 
 
Fig. 7. Metabolic syndrome may be an aspect of “metabolic memory” conceptualized as 
prolonged RAGE activation through subclinical information. 
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